Concurrent use of proton pump inhibitors or h2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia
Yin, Ophelia Q. P. Giles, Frank J. Baccarani, Michele le Coutre, Philipp Chiparus, Ovidiu Gallagher, Neil Saglio, Giuseppe Hughes, Timothy P. Hochhaus, Andreas Kantarjian, Hagop M.
Yin, Ophelia Q. P.
Giles, Frank J.
Baccarani, Michele
le Coutre, Philipp
Chiparus, Ovidiu
Gallagher, Neil
Saglio, Giuseppe
Hughes, Timothy P.
Hochhaus, Andreas
Kantarjian, Hagop M.
Publication Date
2012-05-24
Type
Article
Downloads
Citation
Yin, Ophelia Q. P. Giles, Frank J.; Baccarani, Michele; le Coutre, Philipp; Chiparus, Ovidiu; Gallagher, Neil; Saglio, Giuseppe; Hughes, Timothy P.; Hochhaus, Andreas; Kantarjian, Hagop M.; Larson, Richard A. (2012). Concurrent use of proton pump inhibitors or h2 blockers did not adversely affect nilotinib efficacy in patients with chronic myeloid leukemia. Cancer Chemotherapy and Pharmacology 70 (2), 345-350
Abstract
The impact of proton pump inhibitors (PPIs) and histamine H2 receptor antagonists (H2 blockers) on the efficacy of nilotinib was evaluated. Retrospective analyses were performed in patients with newly diagnosed Philadelphia chromosome-positive (Ph+) chronic myeloid leukemia in chronic phase (CML-CP; N = 492) and in patients with imatinib-resistant or imatinib-intolerant Ph+ CML-CP (N = 256) treated with nilotinib. In the newly diagnosed population, 87 (17.7 %) and 49 (10.0 %) patients received PPIs and H2 blockers, respectively. Major molecular response at 12 months was achieved by 59 (49.6 %) patients who received at least one PPI or H2 blocker (n = 119) and 153 (41.0 %) patients who did not receive any comedication (n = 373; P = 0.13). PPIs and H2 blockers were used by 77 (30.1 %) and 17 (6.6 %) patients with imatinib-resistant or imatinib-intolerant CML-CP, respectively. Major cytogenetic response by 12 months was achieved by 55 (64.0 %) patients who received at least one PPI or H2 blocker (n = 86) versus 98 (57.6 %) patients who did not receive any comedication (n = 170; P = 0.40); 39 (45.3 %) versus 65 (38.2 %), respectively, achieved complete cytogenetic response by 12 months (P = 0.34). Similar findings were observed in patients who received comedication for > 50 % of the time on nilotinib therapy. Nilotinib steady-state trough concentration was not affected by the presence of PPIs or H2 blockers. Concurrent use of PPIs or H2 blockers did not affect the pharmacokinetics and efficacy of nilotinib in patients with Ph+ CML-CP.
Funder
Publisher
Springer Nature
Publisher DOI
Rights
Attribution-NonCommercial-NoDerivs 3.0 Ireland